Cited 291 times in
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2022-02-23T01:21:35Z | - |
dc.date.available | 2022-02-23T01:21:35Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187654 | - |
dc.description.abstract | Purpose: Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. Methods: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, ≥ 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. Results: In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. Conclusion: Amivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy. Trial registration: ClinicalTrials.gov NCT02609776. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Bispecific / administration & dosage* | - |
dc.subject.MESH | Antibodies, Bispecific / adverse effects | - |
dc.subject.MESH | Antibodies, Bispecific / pharmacokinetics | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / administration & dosage* | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / adverse effects | - |
dc.subject.MESH | Antineoplastic Agents, Immunological / pharmacokinetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / genetics | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung / secondary | - |
dc.subject.MESH | Diarrhea / chemically induced | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Drug Eruptions / etiology | - |
dc.subject.MESH | ErbB Receptors / genetics* | - |
dc.subject.MESH | Exons | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypokalemia / chemically induced | - |
dc.subject.MESH | Injection Site Reaction / etiology | - |
dc.subject.MESH | Lung Neoplasms / drug therapy* | - |
dc.subject.MESH | Lung Neoplasms / genetics | - |
dc.subject.MESH | Lung Neoplasms / pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutagenesis, Insertional | - |
dc.subject.MESH | Neutropenia / chemically induced | - |
dc.subject.MESH | Organoplatinum Compounds / therapeutic use | - |
dc.subject.MESH | Paronychia / chemically induced | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Pulmonary Embolism / chemically induced | - |
dc.subject.MESH | Retreatment . | - |
dc.title | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Eric B Haura | - |
dc.contributor.googleauthor | Natasha B Leighl | - |
dc.contributor.googleauthor | Paul Mitchell | - |
dc.contributor.googleauthor | Catherine A Shu | - |
dc.contributor.googleauthor | Nicolas Girard | - |
dc.contributor.googleauthor | Santiago Viteri | - |
dc.contributor.googleauthor | Ji-Youn Han | - |
dc.contributor.googleauthor | Sang-We Kim | - |
dc.contributor.googleauthor | Chee Khoon Lee | - |
dc.contributor.googleauthor | Joshua K Sabari | - |
dc.contributor.googleauthor | Alexander I Spira | - |
dc.contributor.googleauthor | Tsung-Ying Yang | - |
dc.contributor.googleauthor | Dong-Wan Kim | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Rachel E Sanborn | - |
dc.contributor.googleauthor | José Trigo | - |
dc.contributor.googleauthor | Koichi Goto | - |
dc.contributor.googleauthor | Jong-Seok Lee | - |
dc.contributor.googleauthor | James Chih-Hsin Yang | - |
dc.contributor.googleauthor | Ramaswamy Govindan | - |
dc.contributor.googleauthor | Joshua M Bauml | - |
dc.contributor.googleauthor | Pilar Garrido | - |
dc.contributor.googleauthor | Matthew G Krebs | - |
dc.contributor.googleauthor | Karen L Reckamp | - |
dc.contributor.googleauthor | John Xie | - |
dc.contributor.googleauthor | Joshua C Curtin | - |
dc.contributor.googleauthor | Nahor Haddish-Berhane | - |
dc.contributor.googleauthor | Amy Roshak | - |
dc.contributor.googleauthor | Dawn Millington | - |
dc.contributor.googleauthor | Patricia Lorenzini | - |
dc.contributor.googleauthor | Meena Thayu | - |
dc.contributor.googleauthor | Roland E Knoblauch | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1200/JCO.21.00662 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 34339292 | - |
dc.identifier.url | https://ascopubs.org/doi/10.1200/JCO.21.00662 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 30 | - |
dc.citation.startPage | 3391 | - |
dc.citation.endPage | 3402 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.39(30) : 3391-3402, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.